Aesica's High-Capacity Manufacturing Facility in Queenborough Validated for Commercial Production - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica's High-Capacity Manufacturing Facility in Queenborough Validated for Commercial Production


Aesica announced hat it has successfully completed the validation of its high capacity manufacturing facility in Queenborough, UK, for commercial production. The company invested $45 million in this new facility and has expanded commercial production of solid dosages for the treatment of type II diabetes.

The facility has been built with a capacity to produce in excess of 1 billion tablets annually, with future expansion plans to double production to more than 2.5 billion tablets. The advanced unit has been equipped with highly technical and specialist equipment including state-of-the-art spray granulators, coaters, tablet presses, powder handling systems and large capacity blenders. The facility provides a 10,000 m2 expansion to the existing Queenborough site and has a dedicated workforce of 55 technicians.

Source: Aesica

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here